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Abstract
Background: Hyperphosphatemia in patients with chronic kidney disease (CKD) contributes to secondary
hyperparathyroidism, soft tissue calcification, and increased mortality risk. This trial was conducted to examine the
efficacy and safety of calcium acetate in controlling serum phosphorus in pre-dialysis patients with CKD.
Methods: In this randomized, double-blind, placebo-controlled trial, 110 nondialyzed patients from 34 sites with
estimated GFR < 30 mL/min/1.73 m
2 and serum phosphorus > 4.5 mg/dL were randomized to calcium acetate or
placebo for 12 weeks. The dose of study drugs was titrated to achieve target serum phosphorus of 2.7-4.5 mg/dL.
Serum phosphorus, calcium, iPTH, bicarbonate and serum albumin were measured at baseline and every 2 weeks
for the 12 week study period. The primary efficacy endpoint was serum phosphorus at 12 weeks. Secondary
endpoints were to measure serum calcium and intact parathyroid hormone (iPTH) levels.
Results: At 12 weeks, serum phosphorus concentration was significantly lower in the calcium acetate group
compared to the placebo group (4.4 ± 1.2 mg/dL vs. 5.1 ± 1.4 mg/dL; p = 0.04). The albumin-adjusted serum
calcium concentration was significantly higher (9.5 ± 0.8 vs. 8.8 ± 0.8; p < 0.001) and iPTH was significantly lower in
the calcium acetate group compared to placebo (150 ± 157 vs. 351 ± 292 pg/mL respectively; p < 0.001). At 12
weeks, the proportions of subjects who had hypocalcemia were 5.4% and 19.5% for the calcium acetate and the
placebo groups, respectively, while the proportions of those with hypercalcemia were 13.5% and 0%, respectively.
Adverse events did not differ between the treatment groups.
Conclusions: In CKD patients not yet on dialysis, calcium acetate was effective in reducing serum phosphorus and
iPTH over a 12 week period.
Trial Registration: www.clinicaltrials.gov NCT00211978.
Background
Chronic kidney disease (CKD) is a major global health
problem affecting an estimated 5 to 10 percent of the
total world population [1]. In the United States, the pre-
valence of CKD has increased from 10% in 1988-1994
to 13.1% in 1999-2004 with an estimated 26 million
individuals with CKD [2,3]. Of these, more than
8 million are estimated to have a glomerular filtration
rate (GFR) < 60 mL/minute/1.73 m
2.C h r o n i ck i d n e y
disease is associated with increased cost and poor clini-
cal outcomes [1-4]. In addition to the progressive loss of
kidney function over time and the eventual need for
renal replacement therapy, patients with CKD have a
high mortality rate, with cardiovascular disease account-
ing for almost 50% of deaths [3]. In fact, patients with
CKD are more likely to die than progress to end-stage
renal disease (ESRD) [4]. Strong evidence from experi-
mental and clinical studies has documented a major role
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several clinical disorders in patients with CKD [5-13].
Hyperphosphatemia contributes to abnormal bone
metabolism and cardiovascular calcification (CVC);
components of the syndrome of CKD-Mineral and Bone
Disorder (CKD-MBD) [14]. Ample evidence now exists
for the role of hyperphosphatemia in the pathogenesis
of CVC, a risk factor for death from cardiovascular dis-
ease [15-21]. In vitro studies showed that phosphorus
directly stimulates vascular smooth muscle cells to
undergo osteoblastic differentiation and expression of
bone-related proteins that are involved in the develop-
ment and progression of CVC [16,18,20]. More impor-
tant is the association between high serum phosphorus
and increased risk of cardiovascular events and mortal-
ity, both in the CKD population [5,22] as well as in indi-
viduals with normal renal function [23]. On the other
hand, use of phosphate binders decreased vascular calci-
fication in mice [18]. Thus, control of serum phos-
phorus to levels recommended by KDOQI guidelines for
bone and mineral metabolism during earlier stages of
CKD may help reduce cardiovascular morbidity and
mortality [24]. Indeed, treatment with phosphorus bin-
ders was recently shown to be independently associated
with improved survival among incident hemodialysis
patients [6]. If these findings can be substantiated, the
potential benefits of phosphate binders may extend to
the non-dialyzed CKD population. Due to the scarcity of
high-level evidence on the beneficial effect of phosphate
binders on hard study outcomes, however, none of the
currently available phosphate binders have received
approval by the U.S. Food and Drug Administration
(FDA) for use in patients with CKD who do not require
dialysis.
Calcium acetate is an effective phosphate binder that
is routinely used in patients with ESRD [25-27]. The
aim of the present randomized, double-blind, placebo-
controlled trial was to evaluate the efficacy and safety of
calcium acetate in controlling serum phosphorus, cal-
cium, PTH, and Ca × P product in nondialyzed patients
with stage 4 and 5 CKD.
Methods
Study population
The target population was patients with advanced CKD
who did not yet require dialysis and whose serum phos-
phorus was elevated in the absence of phosphate binder
therapy. We hypothesized that calcium acetate would
safely improve such patients’ phosphorus control com-
pared with placebo.
Study Design
This study was a prospective, multicenter, randomized,
double-blind, placebo-controlled efficacy trial to
compare the effect of calcium acetate versus placebo on
the control of serum phosphorus, iPTH, and the cal-
cium-phosphorus product in hyperphosphatemic, pre-
dialysis patients with advanced CKD as defined by a
GFR < 30 mL/min/1.73 m
2. The study protocol and the
informed consent form were reviewed and approved by
the Institutional Review Boards (IRB) of each participat-
ing center and registered at www.clinicaltrials.gov
(NCT00211978.)
Study participants had to be at least 18 years of age,
have an estimated GFR < 30 mL/min/1.73 m
2 as esti-
mated by the four variable Modification of Diet in Renal
Disease (MDRD) equation, and a serum phosphorus >
4.5 mg/mL following a washout period of 6 weeks. Dur-
ing the washout period, all phosphate binders, calcium
supplements, and vitamin D analogues were discontin-
ued if previously taken. Patients were excluded if they
had history of medications non-adherence, gastrointest-
inal motility disorders, or any other conditions that ren-
dered them clinically unstable. All patients signed
written, informed consent prior to the initiation of any
study-related activities.
Patients were instructed to continue their usual diet.
T h es t a r t i n gd o s eo fs t u d yd r u gw a sg u i d e db yt h e
serum phosphorus level at the end of the washout per-
iod. Patients with serum phosphorus levels between 4.5
and 5.0 mg/dL received an initial dose of 1 gelcap per
meal; those with phosphorus levels between 5.1 and 6.0
mg/dL started with 2 gelcaps per meal and those with
phosphorus levels > 6.0 mg/dL were administered a
starting dose of 3 gelcaps per meal. Study participants
returned for follow-up visits every 2 weeks. During
these visits, the dose was titrated up to a maximum of
15 gelcaps per day. If, after 3 months of treatment, the
serum phosphorus level remained > 5.5 mg/dL or the
iPTH was still > 110 pg/mL despite maximum daily
dose of 15 gelcaps, the study protocol required that
such subjects be withdrawn from the study for failure to
control. The use of medications that alter calcium and
phosphorus balance was prohibited throughout the
study. Thus, the use of rescue medications such as other
phosphate binders, calcium supplements or vitamin D
was also considered a study failure.
Serum phosphorus, calcium, iPTH, bicarbonate and
serum albumin were measured at baseline and every
2 weeks throughout the study period. Laboratory sam-
ples were centrally analyzed by LabConnect, Seattle,
WA. Total calcium was corrected for serum albumin.
Calcium and phosphorus were measured as colorimetric
assays on the Olympus 5400 analyzer. Intact PTH levels
and homocysteine were assayed by a chemiluminescent
assay on the Bayer Advia Centaur.
For the purpose of this study, the following recom-
mended KDOQI treatment targets were used to
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target: serum phosphorus of 2.7 to 4.5 mg/dL, and iPTH
of 70 to 110 pg/mL. Target serum calcium was defined
as 8.5 to 10.2 mg/dL adjusted for serum albumin.
Patients were also assessed for compliance with study
medications, adverse events, and use of concomitant
medications during each study visit.
Statistical Analysis
All analyses followed the intention-to-treat (ITT) princi-
ple. The original study plan called for 26 weeks of fol-
low-up with the proportion of weeks within target being
the efficacy measure (see Additional file 1: A for the
original sample-size calculation). As a consequence of
the requirement that participants with uncontrolled
hyperphosphatemia be removed from the study after
3 months, a large proportion of patients in the placebo
group left the study at that time point. Thus, by such
design, informative censoring was introduced into the
study. The present analysis departs from this study plan
and limits observation to 12 weeks from randomization
to reduce such bias. The primary efficacy measure was
the serum phosphorus at 12 weeks. Secondary endpoints
included serum calcium adjusted for serum albumin and
iPTH levels at 12 weeks.
Baseline characteristics were compared using the
2-sample t-test and Pearson’s chi-square tests for con-
tinuous and categorical variables, respectively. Measure-
ments at 12 weeks were also compared using the
2-sample t-test. All statistical tests were two-sided with
a p-value of < 0.05 considered significant. In addition to
the comparison of the biochemical measurements at
12 weeks, the parameters were also assessed throughout
the 12-week observation period, together with the corre-
sponding standard deviations. All analyses were per-
formed using SAS release 9.1.
Results
A total of 235 patients were screened and 110 were ran-
domly allocated to receive calcium acetate (PhosLo
® 667
mg capsules; Fresenius Medical Care North America,
W a l t h a m ,M A ,U S A )o rp l a c e b of o r6m o n t h s .F i g u r e1
provides a flow diagram of subjects from screening to
completion of the study. The most common reason for
screening failure was a serum phosphorus level below
4.5 mg/dL. Forty six subjects were treated with calcium
acetate and 64 with placebo. Randomization errors in
the use of block randomization at 3 study sites as well
as randomization of small numbers of patients per study
site resulted in more subjects randomized to placebo
which contributed to the imbalance. Table 1 demon-
strates, however, that randomization achieved balance of
observed characteristics between treatment groups. Of
the enrolled subjects, 9 (19.6%) subjects in the calcium
acetate group and 23 (39.1%) in the placebo group
dropped out of the study during the first 12 weeks (p =
0.06). As shown in Figure 1, one reason for dropping
out was failure to control serum phosphorus, which was
the reason for withdrawal in 0 and 2 patients in the cal-
cium acetate and placebo groups, respectively. Based on
pill counts obtained at each visit, compliance during the
12 week study period was similar in the two groups:
88.6 ± 15.0% in the calcium acetate group and 89.3 ±
14.0% in the placebo group. Two patients in each group
were withdrawn from the study because they started
dialysis.
Serum phosphorus concentration
Baseline serum phosphorus concentration did not differ
between treatment groups (5.1 ± 1.2 mg/dL vs. 5.1 ± 1.1
mg/dL in calcium acetate and placebo groups, respec-
tively; p = 0.76; Table 1). Serum phosphorus concentra-
tion at 12 weeks, the primary efficacy endpoint, was
significantly lower in the calcium acetate group com-
pared to the placebo group (4.4 ± 1.2 mg/dL vs.5 . 1±
1.4 mg/dL; p = 0.04; Table 2). Figure 2 displays the time
course of serum phosphorus concentrations over the
12 weeks of investigation. The percentage of subjects
with serum phosphorus control to the KDOQI target
was significantly higher in the calcium acetate group
compared with the placebo group (59.5% vs. 36.6%; p =
0.04; Figure 3).
Serum calcium concentration
Serum calcium concentrations, adjusted for serum albu-
min, did not differ between the randomized groups at
baseline (9.1 ± 0.7 vs. 9.1 ± 0.6; p = 0.97; Table 1). After
12 weeks of study, subjects in the calcium acetate group
had significantly higher albumin-adjusted serum calcium
concentrations compared with the placebo group (9.5 ±
0.8 vs. 8.8 ± 0.8; p < 0.001; Table 2) (Figure 4). The pro-
portion of subjects within the target range, however, did
not differ between treatment groups (81.1% vs. 71.8%;
p = 0.34; Figure 5). Most subjects outside the target
range in the calcium acetate group were above the
upper limit (5 patients; 13.5% of total), whereas no pla-
cebo treated subject was above the targeted range in the
placebo group. At 12 weeks, the percentage of subjects
who had hypocalcemia was 5.4% and 19.5% for the cal-
cium acetate and the placebo groups respectively while
the proportions of those with hypercalcemia were 13.5%
and 0%, respectively. There were 18 episodes of hyper-
calcemia in the calcium acetate group and 5 in the
placebo group.
Intact parathyroid hormone concentrations (iPTH)
Serum concentrations of iPTH did not differ between
treatment groups at baseline (Table 1). At 12 weeks,
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Page 3 of 12235 Assessed for eligibility
125 excluded
102 inclusion criteria
12 refused to participate
11 were not enrolled for other reasons 
Completed by Week 12 (n=37)
46 allocated to Calcium Acetate
All received allocated intervention
44 discontinued subjects
Reason for discontinuation
0-12 weeks      After 12 weeks 
n                           n
Death                                    1                           2
Lost to follow-up                  0                            1
Non-compliance                   3                            0
Protocol violation                 7                            0
Withdraw consent                 2                            1
Adverse event                       4                            2
Failure to control phos          2                          15
Other                                     4                            0
Subtotal                              23                           21
110 Randomized
64 allocated to Placebo
All received allocated intervention
Completed by Week 12 (n=41)
18 early discontinued subjects
Reason for discontinuation  
0-12 weeks      After 12 weeks 
n                           n
Death                                    1                           0
Lost to follow-up                  0                           0
Non-compliance                   1                           1
Protocol violation                 0                           0
Withdraw consent                3                            0
Adverse event                      2                            3
Failure to control phos         0                            4
Other                                    2                            1
Subtotal                               9                            9
Completed study (n=20) Completed study (n=28)
Figure 1 Patient disposition from screening to end of study.
Table 1 Baseline Characteristics
Characteristic Calcium acetate
(N = 46)
Placebo
(N = 64)
P-value
Age (years) 63.2 ± 11.7 62.2 ± 14.2 0.69
Gender (female) 23 (50%) 29 (45.3%) 0.63
Race (white) 33 (71.7%) 54 (84.4%) 0.34
Diabetes 31 (67.4%) 49 (76.6%) 0.29
Weight (Kg) 82.9 ± 23.2 80.8 ± 25.6 0.65
Serum phosphorus (mg/dL) 5.1 ± 1.2 5.1 ± 1.1 0.76
Serum calcium, corrected (mg/dL) 9.1 ± 0.7 9.1 ± 0.6 0.97
Intact parathyroid hormone (pg/mL)
1 253 ± 213 322 ± 267 0.16
Serum albumin (mg/dL) 3.6 ± 0.5 3.5 ± 0.5 0.56
Serum bicarbonate (mEq/L) 22.6 ± 3.9 21.9 ± 3.7 0.33
Estimated glomerular filtration rate (mL/min/1.73 m
2) 17.3 ± 5.6 16.4 ± 6.2 0.43
1Available in 45 and 56 patients in the calcium acetate and placebo groups, respectively.
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Page 4 of 12however, iPTH was significantly lower in the calcium
acetate group compared with placebo (150 ± 157 vs. 351
± 292 pg/mL; p < 0.001; Figure 6). Suppression of iPTH
in the treatment group was apparent after 2 weeks of
treatment (Figure 6). While only 45.9% of subjects in
the calcium acetate group had an iPTH concentration
above 110 pg/dL after 12 weeks, almost all subjects had
elevated iPTH in the placebo group at that time point
(92.3%; p < 0.001; Figure 7).
Safety and tolerability
During 12 weeks of follow up, 65.2% of subjects in the
calcium acetate and 65.6% of subjects in the placebo
group reported at least one adverse event (p = 0.96;
Table 2 Comparison of study endpoints at 12 weeks by
randomized treatment assignment
Characteristic Calcium
acetate
(N = 37)
Placebo
(N = 41)
P-value
Serum phosphorus (mg/dL) n = 37
4.4 ± 1.2
n=3 6
5.1 ± 1.4
0.04
Serum calcium,
corrected (mg/dL)
n=3 7
9.5 ± 0.8
n=3 6
8.8 ± 0.8
< 0.001
Intact parathyroid
hormone (pg/mL)
n=3 5
150 ± 157
n=3 8
351 ± 292
< 0.001
Serum bicarbonate (mEq/L) n = 35
24.0 ± 3.7
n=3 5
21.6 ± 3.8
0.008
Serum albumin (mg/dL) n = 37
3.6 ± 0.5
n=3 6
3.5 ± 0.5
0.34
Figure 2 Serum phosphorus concentration (mg/dL) from randomization to 12 weeks.
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Page 5 of 12Table 3). The rates of adverse events in general did not
differ between study groups: 0.42 versus 0.57 events per
subject per visit in the calcium acetate and placebo
groups, respectively (p = 0.46). Adverse events deemed
related to the study drug, were relatively rare: 10.9% and
14.1% of patients in the calcium acetate and placebo
groups experienced at least 1 event (p =0 . 1 6 ) .T h er a t e
of related adverse events also did not differ between
study groups (p = 0.84). Additional file 1: B displays all
adverse events and related adverse events in each study
group in full detail
Discussion
KDOQI guidelines recommend that serum phosphorus
be maintained within the target range of 2.7 to 4.6 mg/
dL in stages 3 and 4 CKD and 3.5 to 5.5 mg/dL in stage
5 CKD by means of dietary phosphate restriction, dialy-
sis and use of phosphate binders [24]. In this study, cal-
cium acetate resulted in reduction of the mean serum
phosphorus to recommended levels in pre-dialysis
patients with advanced CKD compared with placebo
(4.4 ± 1.2 mg/dL vs. 5.1 ± 1.4 mg/dL, respectively; p =
0.04). The percentage of subjects whose serum phos-
phorus concentration fell within target was significantly
higher in the calcium acetate group compared with pla-
cebo (59.5% vs. 36.6% p = 0.04; Figure 3).
Phosphate binders are approved for the treatment of
hyperphosphatemia in patients receiving maintenance
dialysis based on their efficacy on the endpoint of phos-
phorus and possibly PTH control. Their efficacy in redu-
cing relevant endpoint such as morbidity or mortality
has never been established. One study has demonstrated
a beneficial association between receipt of phosphorus
binder (calcium-based or non-calcium based), but it can-
not be ruled out that patients receiving phosphate bin-
ders were systematically healthier [6]. Given that CKD is
a clinical continuum and that a serum phosphorus level
greater than 3.5 mg/dL is an independent predictor of
all-cause mortality in dialyzed and non-dialyzed patients
[5,22,23], it is also possible that controlling elevated
serum phosphorus concentrations may yield beneficial
results, but this remains to be shown in randomized
trials. None of the currently available phosphate binders
are approved by the FDA for use in pre-dialysis patients.
The present study is the first to provide unequivocal evi-
dence from a randomized trial that calcium acetate is
efficacious in reducing serum phosphorus concentrations
in patients with predialysis CKD. As a phosphate binder,
Figure 3 Proportion (%) of patients in, below, or above the target range of serum phosphorus concentration (2.7-4.5 mg/dL) at
12 weeks.
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in non-dialyzed CKD patients. First, as shown in this
trial, calcium acetate is clearly effective in controlling
serum phosphorus to levels recommended by KDOQI
guidelines. One could assume that achieving these tar-
gets in CKD patients is associated with a reduction in
the risk of developing cardiovascular calcification and
bone disease and a reduction in the risk of death. Treat-
ment with any of the available phosphate binders was
shown to be independently associated with improved
survival among incident hemodialysis patients [6]. In
addition, calcium acetate can correct hypocalcemia
which is a critical factor in stimulating PTH secretion
and induction of parathyroid gland hyperplasia. During
this study, hypocalcemia was observed in 5.4% and 19.5%
for the calcium acetate and the placebo groups respec-
tively. On the other hand, there was a small but signifi-
cant increase in serum calcium in the calcium acetate
group rendering it more effective than placebo in sup-
pressing PTH secretion (Table 2 and Figure 6). Calcium
acetate has a salutary effect on acidosis which is known
to contribute to the pathogenesis of renal bone disease,
malnutrition and inflammation [28,29]. The acetate
anion is metabolized to bicarbonate which helps to cor-
rect metabolic acidosis, a common abnormality in non-
dialyzed CKD patients [29]. The serum bicarbonate level
at the end of our study was significantly higher in cal-
cium acetate treated subjects than in those in the pla-
cebo group (24.0 ± 3.7 vs. 21.6 ± 3.8 mEq/L respectively;
p-value 0.008).
Calcium acetate was well tolerated and exhibited a
safety profile similar to placebo. The most frequent
adverse events in calcium acetate-treated subjects were
gastrointestinal events as well as “infections and infesta-
tions”, both not significantly different from those
recorded in the placebo group.
Figure 4 Serum calcium concentration (mg/dL) from randomization to 12 weeks.
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Page 7 of 12Figure 5 Proportion (%) of patients in, below, or above the target range of serum calcium concentration (8.5-10.2 mg/dL) at
12 weeks.
Figure 6 Serum intact parathyroid hormone concentration (pg/mL).
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phosphate binders in non-dialyzed CKD patients
[30-32]. Borrego and colleagues compared the efficacy
of calcium carbonate vs. calcium acetate as phosphate
binders in 28 patients with CKD (mean creatinine clear-
ance 21 ml/min) [30]. These authors found that both
d r u g sw e r es i m i l a r l ye f f e c t i v ea sp h o s p h a t eb i n d e r si n
lowering serum phosphate levels. The carbonate group,
though, required a four-fold greater dose of calcium
than the acetate group and exhibited more hypercalce-
mic episodes [30]. In another study, Ketteler et al
showed that sevelamer carbonate is effective in control-
ling serum phosphorus in CKDp a t i e n t s[ 3 1 ] .H o w e v e r ,
their study design was an open-label, single-arm 8 week
Figure 7 Proportion (%) of patients in, below, or above the target range of serum parathyroid hormone level (70-110 pg/mL) at 12
weeks.
Table 3 Adverse events prior to week 14
Adverse Event Outcome Calcium acetate
(N = 46)
Placebo
(N = 64)
P-value
Patients with any adverse event 30 (65.2%) 42 (65.6%) 0.96
Any adverse event, rate (per subject per visit) 0.42 0.57 0.46
Patients with related adverse event 5 (10.9%) 9 (14.1%) 0.16
Related adverse event, rate (per subject per visit) 0.39 0.36 0.84
Adverse events related to medication by organ system class
Cardiac disorders 0 1 (1.6%)
Gastrointestinal disorders 3 (6.5%) 6 (9.4%)
General disorders 1 (2.2%) 0
Investigations 1 (2.2%) 0
Metabolism and nutrition disorders 2 (4.3%) 1 (1.6%)
Musculoskeletal and connective tissue disorders 0 1 (1.6%)
Skin and subcutaneous tissue disorders 0 1 (1.6%)
Vascular disorders 0 1 (1.6%)
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and placebo-controlled 12 week study. Moreover, sub-
jects in their study were required to have serum phos-
phate level of ≥ 5.5 mg/dl for enrollment in contrast to
the > 4.5 mg/dl in our study. Finally, the iPTH level was
reduced to a lower level in our study, obviating the need
for administration of other drugs that suppress PTH
secretion. Conversely, Ketteler and colleagues prescribed
a daily dose of 400 IU of the native form of vitamin D
during the treatment period and several subjects in their
study were continued on pre-study 1,25 dihydroxyvita-
min D and/or cinacalcet. A more recent study by Sprague
et al reported the efficacy and safety of lanthanum carbo-
nate in 121 patients with CKD stages 3 and 4 for 8 weeks
with 90 patients completing the study [30]. Their study
and ours were similar in that both were randomized, dou-
ble-blind, placebo-controlled trials. However, our study
was for slightly longer duration (12 weeks vs. 8 weeks) and
a higher percentage of out calcium acetate-treated subjects
achieved serum phosphorus levels within target compared
to their study subjects (59.5% versus 44.6% respectively).
A major limitation of our study is the drop-out rate
and withdrawal rate for failure to control serum phos-
phorus or iPTH levels. In order to address the impact of
the dropouts, an ITT analysis was used where all
patients who received at least one dose of the study
drug were included. This conservative analysis which
was based on all randomized subjects may have lowered
the percentage of those who achieved target serum
phosphorus and iPTH levels in calcium acetate-treated
patients. Urinary excretion of phosphorus was not mea-
sured in this trial. Previous studies have shown that
administration of phosphate binders resulted in a signifi-
cant decrease in urinary phosphorus excretion in CKD
patients [30,31]. Finally, the present study did not exam-
ine patients’ outcomes as this usually requires a much
larger sample size. However, a previous study has shown
that high serum phosphorus concentrations in patients
with CKD was associated with significantly greater pro-
gression of coronary artery calcification (CAC) even in
patients whose serum phosphorus was within the nor-
mal range [21]. Treatment with phosphate binders stabi-
lized or even decreased progression of CAC in these
patients [33]. However, although serum calcium levels
might be normal, it is possible to develop a positive cal-
cium balance when high doses of calcium based binders
are used. Thus, further investigations are warranted in
order to assess the long-term effects of chronic treat-
ment with calcium-based or non-calcium containing in
patients with non-dialysis-dependent CKD.
Conclusion
The results of this study demonstrated that calcium
acetate is efficacious and safe in controlling serum
phosphorus, calcium, iPTH and serum bicarbonate in
non-dialyzed CKD patients. Additional studies are
clearly required, not only to study the efficacy and safety
of phosphate binders in CKD patients, but also to inves-
tigate their impact on patient outcomes.
Additional material
Additional file 1: A. Sample size calculation in the original study
protocol. File contains calculation of the sample size. B. Adverse Events
(AE) in the calcium acetate and placebo groups. File contains all adverse
events in the study subjects.
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